株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

がん免疫学と腫瘍溶解性ウィルス学:技術と世界市場

Cancer Immunology and Oncolytic Virology: Technologies and Global Markets

発行 BCC Research 商品コード 298488
出版日 ページ情報 英文 106 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: BCC Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
がん免疫学と腫瘍溶解性ウィルス学:技術と世界市場 Cancer Immunology and Oncolytic Virology: Technologies and Global Markets
出版日: 2014年03月28日 ページ情報: 英文 106 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

免疫学に基づくがんの治療法は、近年新たに開発された技術であり、革新的な新薬へのニーズが高まるなか、急速に発展しつつあります。世界のがん免疫療法市場における売上高は、2012年の308億ドルから2018年には689億ドルに拡大すると見られており、この間の年平均成長率は14.7%になります。

当レポートは、がん免疫療法の世界市場を概観し、2012年と13年のデータから世界的な市場のトレンドを分析するとともに、2018年までの見通しを示したもので、臨床ガイドラインや人口構成の変化、市場の成熟など需要に影響を及ぼす要因と特許を含めた技術面の分析に加え、主要メーカーのプロファイルも盛り込み、概略以下の構成でお届けします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • がん免疫学の歴史と現状
    • がんのタイプ
    • がん治療のタイプ
      • 手術
      • 放射線療法
      • 薬物治療
      • 免疫療法
      • 炎症反応
    • がんの治療が困難な理由
    • 臨床的に重要ながん
      • 前立腺がん
      • 慢性リンパ球性白血病(CLL)
      • 乳がん
      • 転移性黒色腫
      • 卵巣がん
      • 子宮頸がん
      • 頭頚部がん
      • 肺がん
      • 脳腫瘍
      • 多発性骨髄腫
      • すい臓がん
  • 2018年までの世界的ながんのトレンドに関するサマリー
  • 進行がんの原因となる可能性の高い環境
    • 遺伝
    • 放射線被曝
    • 化学的発がん物質への暴露
    • 生物学的発がん物質への暴露
  • ヒトのがんに関する研究開発

第4章 がん免疫療法の概要

  • 作用機序
    • ヒトの免疫システム
    • T細胞
    • PD-1およびPD-L1阻害剤
  • 生物反応修飾物質
    • コロニー刺激因子
    • インターフェロン
    • インターロイキン製品
    • 治療用モノクローナル抗体
  • がんワクチン
    • がんを防ぐためのワクチン
    • 治療用がんワクチン
      • 黒色腫
      • 乳がん
      • 子宮頸がん
      • 卵巣がん
      • 腎細胞がん
      • 肺がん
      • すい臓がん
      • 前立腺がん
  • がん治療のための他の免疫療法製品
    • GLEEVEC
    • IRESSA
    • KYPROLIS
    • NEXAVAR
    • POMALYST
    • SUTENT
    • TARCEVA
    • TYKERB
    • VELCADE
  • 一部臨床試験段階の医薬品に関する補足情報

第5章 腫瘍溶解性ウィルス療法

  • ウィルス療法
  • 腫瘍溶解性ウィルス学
    • がん治療へのHIVの応用
    • ウィルスを利用した小児がん治療
    • 腫瘍溶解性ウィルス学の分野における企業の動き
  • がん免疫療法とウィルス学の分野におけるニュースと契約
  • 各国政府の規制
  • 業界の構造
  • 腫瘍溶解性ウィルスの研究に関わっている企業

第6章 主な市場

  • 腫瘍溶解性ウィルス製品の市場

第7章 技術

  • モノクローナル抗体の生産
    • 抗体薬物複合体
    • キメラ抗原受容体(CAR)発現T細胞技術
  • 特許の評価
    • カナダのモノクローナル抗体技術
    • インドの知的財産権保護問題
    • 新たに発行された特許

第8章 主要企業のプロファイル

  • ABLYNX NV
  • ADURO BIOTECH, INC.
  • ADVAXIS INC.
  • ASTRAZENECA U.S.
  • BRISTOL-MYERS SQUIBB
  • CELGENE CORP.
  • DENDREON CORP.
  • DNATRIX, INC.
  • GENENTECH, A MEMBER OF THE ROCHE GROUP
  • GLAXOSMITHKLINE
  • GLOBEIMMUNE, INC.
  • IMMATICS BIOTECHNOLOGIES GMBH
  • IMMUNOMEDICS, INC.
  • IMMUNOVACCINE, INC.
  • JANSSEN BIOTECH INC./JOHNSON & JOHNSON
  • JENNEREX BIOTHERAPEUTICS INC.
  • MEDIMMUNE LLC (ASTRAZENECA)
  • MEDIVATION INC.
  • MERCK & CO.
  • NORTHWEST BIOTHERAPEUTICS, INC.
  • NOVARTIS INTERNATIONAL AG
  • NOVARTIS PHARMACEUTICALS CORP.
  • ONCOMED PHARMACEUTICALS INC.
  • PFIZER INC.
  • ROCHE (F. HOFFMAN-LA ROCHE AG)
  • VIRALYTICS, LTD.

図表リスト

目次
Product Code: PHM129A

The global cancer immunotherapies market reached $30.8 billion in 2012. This market is expected to grow to nearly $34.3 billion in 2013 and $67.9 billion in 2018 with a compound annual growth rate (CAGR) of 14.7% over the five-year period, 2013 to 2018.

This report provides:

  • An overview of the global market for cancer immunotherapies
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of CAGRs through 2018.
  • Analyses of factors influencing market demand such as clinical guidelines, demographic changes, and market saturation
  • Technological discussion including the current state, newly issued patents, and pending applications
  • Profiles of leading companies in the industry.

STUDY GOALS AND OBJECTIVES

This report, PHM129A Cancer Immunology and Oncolytic Virology: Technologies and Global Markets provides an overview of the current and potential global market for cancer immunotherapy and virology. The report provides comprehensive information on a number of the most common cancers, highlighting global incidence and prevalence. It identifies the need for more effective drugs for treatment of these diseases. The key objective is to present a comprehensive analysis of the current state of cancer immunotherapy and where this field is going. A second objective is to examine the current state of oncolytic virology and where this nascent field appears to be heading. Important trends in each field, clinical trials and results, new developments and sales forecasts for cancer immunotherapy from 2011 through 2018 are provided in this report. In addition, sales forecasts are presented for oncolytic virology covering the years 2011 through 2023. Issues and trends addressed in this report are based on information from industry sources, regulatory and healthcare policies, demographics and other factors that directly affect the cancer market. The report also addresses opportunities for future players.

REASONS FOR DOING THE STUDY

This study was conducted to provide detailed information regarding the new area of immunology-based treatment options for cancer. There is an increasing need for new and innovative drugs. This young industry is experiencing tremendous growth. Many diseases discussed in this report are global issues, and a need exists for newer, more efficacious treatment strategies. This study looks at the latest types of treatment strategies based on immunology, as well as the new field of oncolytic virotherapy, a field still in its infancy showing immense promise for the clinical management of cancer.

This BCC Research market research report will increase the reader's awareness of current and emerging drugs and technologies for many cancers.

SCOPE OF REPORT

The scope of this study entails the current immunology therapeutics markets for several of the most common cancers. The sectors covered are colony stimulating factors (CSFs), interferon alfa and gamma products, interleukin products and therapeutic monoclonal antibodies, including antibody conjugates, cancer vaccines and other cancer treatment immunology products. Vaccines against HPV and hepatitis B are included; while such vaccines act only indirectly against cancer, they do serve to protect against the disease. Also covered is oncolytic virology, so new that its market tables have been presented separately from the immunotherapy tables. The report also includes discussion of the regulatory environment, current and developing technologies, cancer incidence, market projections and market share, along with latest trends and clinical trials.

ANALYST CREDENTIALS

Valerie Kellogg is an experienced medical device and pharmaceutical professional with international market research experience. She has authored numerous reports on topics ranging from treatment of obesity to ablation devices, from wound care to treatment of chronic migraine. Her strong focus areas include treatment of chronic disease, the latest in surgical devices and analysis of potential acquisitions.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH ONLINE SERVICES
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: CANCER IMMUNOTHERAPIES MARKET BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE: CANCER IMMUNOTHERAPIES MARKET BY GEOGRAPHICAL REGION, 2011-2018 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • HISTORY AND CURRENT STATE OF CANCER IMMUNOLOGY
    • CANCER TYPES
    • TYPES OF CANCER TREATMENT
      • Surgery
      • Radiation Therapy
      • Pharmaceutical Therapy
      • Immunotherapy
      • Inflammatory Response
    • WHY IS CANCER SO DIFFICULT TO CURE?
      • Treatment-resistant Cancer
      • Strategies to Improve Response and Decrease Mortality
      • Pre-emptive Therapy
      • Early Stage vs. Advanced Cancer
    • MOST CLINICALLY SIGNIFICANT HUMAN CANCERS
      • Prostate Cancer
        • TABLE 1: GLOBAL PROSTATE CANCER INCIDENCE AND MORTALITY, 2012
      • Diagnosis
      • Treatment
      • Prognosis
      • Chronic Lymphocytic Leukemia (CLL)
        • TABLE 2: GLOBAL LEUKEMIA INCIDENCE AND MORTALITY, 2012
      • Diagnosis
      • Treatment
      • Prognosis
      • Breast Cancer
        • TABLE 3: GLOBAL BREAST CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)
        • TABLE 4: BREAST CANCER INCIDENCE, 2012 (NUMBER)
      • Diagnosis
      • Treatment
      • Prognosis
        • TABLE 5: PROGNOSIS OF BREAST CANCER BASED UPON STAGE (%)
      • Metastatic Melanoma
        • TABLE 6: GLOBAL MELANOMA CANCER INCIDENCE AND MORTALITY, 2012 (NUMBER)
      • Diagnosis
      • Treatment
      • Prognosis
      • Ovarian Cancer
        • TABLE 7: GLOBAL OVARIAN CANCER INCIDENCE AND MORTALITY, 2012 (NUMBER)
      • Diagnosis
      • Treatment
      • Prognosis
        • TABLE 8: RELATIVE FIVE-YEAR SURVIVAL RATE FOR INVASIVE EPITHELIAL OVARIAN CANCER (%)
      • Cervical Cancer
        • TABLE 9: GLOBAL CERVICAL CANCER INCIDENCE AND MORTALITY, 2012 (NUMBER)
      • Diagnosis
      • Treatment
        • TABLE 10: AVASTIN SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
      • Prognosis
        • TABLE 11: FIVE-YEAR RELATIVE SURVIVAL OF CERVIX UTERI CANCER PATIENTS, BASED ON STAGE AT DIAGNOSIS (%)
      • Head and Neck Cancer
        • Diagnosis
        • Treatment
        • Prognosis
      • Lung Cancer
        • TABLE 12: GLOBAL LUNG CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)
      • Diagnosis
        • TABLE 13: STAGES OF LUNG CANCER
      • Treatment
      • Prognosis
        • TABLE 14: NON-SMALL CELL LUNG CANCER FIVE-YEAR SURVIVAL RATES BY STAGE (%)
      • Brain Cancer
        • TABLE 15: GLOBAL BRAIN CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)
      • Diagnosis
      • Treatment
      • Prognosis
      • Multiple Myeloma
        • TABLE 16: GLOBAL MULTIPLE MYELOMA CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)
      • Diagnosis
      • Treatment
      • Prognosis
      • Pancreatic Cancer
        • TABLE 17: GLOBAL PANCREATIC CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)
      • Diagnosis
      • Treatment
      • Prognosis
        • TABLE 18: EXOCRINE PANCREATIC CANCER FIVE-YEAR SURVIVAL RATE (%)
  • SUMMARY OF GLOBAL HUMAN CANCER TRENDS THROUGH 2018
    • TABLE 19: GLOBAL HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • FIGURE 1: GLOBAL HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 20: U.S. HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 21: CANADIAN HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 22: EUROPEAN HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 23: JAPANESE HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 24: REST OF WORLD HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
  • CIRCUMSTANCES MOST LIKELY TO LEAD TO ADVANCED CANCERS
    • Genetics
    • Exposure to Radiation
    • Exposure to a Chemical Carcinogen
      • TABLE 25: KNOWN OCCUPATIONAL EXPOSURE RISKS ASSOCIATED WITH CANCER
    • Exposure to a Biological Carcinogen
  • HUMAN CANCER R&D

CHAPTER 4 - OVERVIEW OF CANCER IMMUNOTHERAPY

  • MECHANISMS OF ACTION
    • HUMAN IMMUNE SYSTEM
    • T CELLS
    • PD-1 AND PD-L1 BLOCKERS
  • BIOLOGICAL RESPONSE MODIFIERS
    • COLONY-STIMULATING FACTORS
      • TABLE 26: COLONY-STIMULATING FACTORS ON THE MARKET
    • INTERFERONS
      • TABLE 27: SELECTED INTERFERON PRODUCTS ON THE MARKET
    • INTERLEUKIN PRODUCTS
      • TABLE 28: SELECTED DEVELOPMENTS IN INTERLEUKINS FOR CANCER THERAPY
    • THERAPEUTIC MONOCLONAL ANTIBODIES
      • TABLE 29: SELECTED APPROVED MONOCLONAL ANTIBODIES
      • TABLE 30: ELECTED MABS IN CLINICAL TESTING FOR INITIAL APPROVAL OR FOR ADDITIONAL INDICATIONS
  • CANCER VACCINES
    • VACCINES TO PROTECT AGAINST CANCER
    • THERAPEUTIC CANCER VACCINES
      • Melanoma
      • Breast Cancer
      • Cervical Cancer
      • Ovarian Cancer
      • Renal Cell Carcinoma
      • Lung Cancer
      • Pancreatic Cancer
      • Prostate Cancer
        • Sipuleucel-T
        • DCVax-Prostate
  • OTHER IMMUNOTHERAPY PRODUCTS FOR CANCER TREATMENT
    • GLEEVEC
    • IRESSA
    • KYPROLIS
    • NEXAVAR
    • POMALYST
    • SUTENT
    • TARCEVA
    • TYKERB
    • VELCADE
      • TABLE 31: SELECTED CLINICAL TRIALS OF IMMUNOTHERAPY PRODUCTS
  • EXPANDED INFORMATION REGARDING SELECTED CLINICAL TRIALS
    • ROCHE'S MPDL3280A TRIAL
    • AMGEN'S ASPECCT TRIAL
    • SEATTLE GENETICS, MILLENNIUM/TAKEDA TRIAL OF ADCETRIS (NCT01896999)
    • BMS AND ABBVIE'S ELOQUENT-1 AND -2 TRIALS
    • BMS AND NIVOLUMAB WITH OR WITHOUT YERVOY
    • BMS AND YERVOY FOR METASTATIC PROSTATE CANCER
    • MERCK AND LAMBROLIZUMAB (MK-3475)

CHAPTER 5 - ONCOLYTIC VIROTHERAPY

  • VIROTHERAPY
  • ONCOLYTIC VIROLOGY
    • USING HIV TO TREAT CANCER
    • TREATING PEDIATRIC CANCERS WITH VIRUSES
    • CORPORATE DEVELOPMENTS IN ONCOLYTIC VIROLOGY
      • BioVex, Amgen and Talimogene Laherparepvec
      • Oncorine
      • DNX-2401
      • PV701 and Newcastle-Disease Virus (NDV)
      • Picornaviruses
  • NEWS AND DEALS IN CANCER IMMUNOTHERAPY AND VIROLOGY
    • NOVARTIS, UNIVERSITY OF PENNSYLVANIA AND CART TECHNOLOGY
    • CELGENE AND ONCOMED PHARMACEUTICALS
    • SEATTLE GENETICS
    • BRISTOL-MYERS SQUIBB
    • MERCK & CO. AND GSK
    • TAKEDA'S MAB LICENSING DEAL WITH IMMUNOMEDICS
    • GENENTECH/ROCHE AND PERTUZUMAB
    • MERCK KGAA AND STIMUVAX
    • ROCHE AND IMMATICS BIOTECHNOLOGIES GMBH SIGN COLLABORATION DEAL
    • MEDIGENE AG AND TRIANTA IMMUNOTHERAPIES
  • GOVERNMENT REGULATIONS
    • U.S. FOOD AND DRUG ADMINISTRATION
    • FDA AND BREAKTHROUGH THERAPY DESIGNATION (BTD)
    • EUROPEAN REGULATORY AUTHORITIES
    • THE U.K.'S VERSION OF THE FDA'S BTD
  • INDUSTRY STRUCTURE
    • MAJOR COMPANIES AND MARKET SHARE
      • FIGURE 2: MARKET SHARES OF LEADERS IN CANCER IMMUNOLOGY, 2013 (%)
  • ONCOLYTIC VIROLOGY COMPANIES

CHAPTER 6 - MAJOR MARKETS

  • TABLE 32: GLOBAL MARKET FOR CANCER IMMUNOLOGY BY SEGMENT, THROUGH 2018 ($ MILLIONS)
  • TABLE 33: VALUE OF CANCER IMMUNOLOGY PRODUCTS IN THE U.S., THROUGH 2018 ($ MILLIONS)
  • TABLE 34: VALUE OF CANCER IMMUNOLOGY PRODUCTS IN CANADA THROUGH 2018 ($ MILLIONS)
  • TABLE 35: VALUE OF CANCER IMMUNOLOGY PRODUCTS IN THE EU THROUGH 2018 ($ MILLIONS)
  • TABLE 36: VALUE OF CANCER IMMUNOLOGY PRODUCTS IN JAPAN, THROUGH 2018 ($ MILLIONS)
  • TABLE 37: VALUE OF CANCER IMMUNOLOGY PRODUCTS FOR REST OF WORLD, (THROUGH 2018) ($ MILLIONS)
  • TABLE 38: CANCER IMMUNOLOGY MARKET BY INDICATION, THROUGH 2018 ($ MILLIONS)
  • TABLE 39: CANCER IMMUNOLOGY SALES BY INDICATION (PROSTATE CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 40: CANCER IMMUNOLOGY SALES BY INDICATION (BREAST CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 41: CANCER IMMUNOLOGY SALES BY INDICATION (LUNG CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 42: CANCER IMMUNOLOGY SALES BY INDICATION (BRAIN CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 43: CANCER IMMUNOLOGY SALES BY INDICATION (HEAD & NECK CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 44: CANCER IMMUNOLOGY SALES BY INDICATION (OVARIAN CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 45: CANCER IMMUNOLOGY SALES BY INDICATION (CERVICAL CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 46: CANCER IMMUNOLOGY SALES BY INDICATION (PANCREATIC CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 47: CANCER IMMUNOLOGY SALES BY INDICATION (MELANOMA CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 48: CANCER IMMUNOLOGY SALES BY INDICATION (OTHER CANCERS) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 49: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: COLONY STIMULATING FACTORS, THROUGH 2018 ($ MILLIONS)
  • TABLE 50: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: INTERFERON ALFA AND GAMMA PRODUCTS, THROUGH 2018 ($ MILLIONS)
  • TABLE 51: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: INTERLEUKIN PRODUCTS, THROUGH 2018 ($ MILLIONS)
  • TABLE 52: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: THERAPEUTIC MONOCLONAL ANTIBODIES, THROUGH 2018 ($ MILLIONS)
  • TABLE 53: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: CANCER VACCINES, THROUGH 2018 ($ MILLIONS)
  • TABLE 54: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: OTHER CANCER TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2018 ($ MILLIONS)
  • MARKET FOR ONCOLYTIC VIROLOGY PRODUCTS
    • TABLE 55: GLOBAL ONCOLYTIC VIROTHERAPY MARKET, THROUGH 2023 ($ MILLIONS)
    • TABLE 56: ONCOLYTIC VIROTHERAPY MARKET BY REGION, THROUGH 2023 ($ MILLIONS)
    • TABLE 57: ONCOLYTIC VIROLOGY OUTLOOK BY CANCER TYPE, THROUGH 2023 ($ MILLIONS)

CHAPTER 7 - TECHNOLOGY

  • PRODUCTION OF MONOCLONAL ANTIBODIES
    • ANTIBODY-DRUG CONJUGATES
    • CAR T-CELL TECHNOLOGY
  • PATENT EVALUATION
    • CANADA AND MONOCLONAL ANTIBODIES
    • INDIA AND (LACK OF) INTELLECTUAL PROPERTY PROTECTION
    • NEWLY ISSUED PATENTS
      • TABLE 58: SELECTED PATENTS IN CANCER IMMUNOLOGY AND VIROLOGY, 2005 TO 2013

CHAPTER 8 - COMPANY PROFILES

  • SELECTED COMPANY PROFILES
    • ABLYNX NV
    • ADURO BIOTECH, INC.
    • ADVAXIS INC.
    • ASTRAZENECA U.S.
    • BRISTOL-MYERS SQUIBB
    • CELGENE CORP.
    • DENDREON CORP.
    • DNATRIX, INC.
    • GENENTECH, A MEMBER OF THE ROCHE GROUP
    • GLAXOSMITHKLINE
    • GLOBEIMMUNE, INC.
    • IMMATICS BIOTECHNOLOGIES GMBH
    • IMMUNOMEDICS, INC.
    • IMMUNOVACCINE, INC.
    • JANSSEN BIOTECH INC./JOHNSON & JOHNSON
    • JENNEREX BIOTHERAPEUTICS INC.
    • MEDIMMUNE LLC (ASTRAZENECA)
    • MEDIVATION INC.
    • MERCK & CO.
    • NORTHWEST BIOTHERAPEUTICS, INC.
    • NOVARTIS INTERNATIONAL AG
    • NOVARTIS PHARMACEUTICALS CORP.
    • ONCOMED PHARMACEUTICALS INC.
    • PFIZER INC.
    • ROCHE (F. HOFFMAN-LA ROCHE AG)
    • VIRALYTICS, LTD.

LIST OF TABLES

  • SUMMARY TABLE CANCER IMMUNOTHERAPIES MARKET BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 1: GLOBAL PROSTATE CANCER INCIDENCE AND MORTALITY, 2012
    • TABLE 2: GLOBAL LEUKEMIA INCIDENCE AND MORTALITY, 2012
    • TABLE 3: GLOBAL BREAST CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)
    • TABLE 4: BREAST CANCER INCIDENCE, 2012 (NUMBER)
    • TABLE 5: PROGNOSIS OF BREAST CANCER BASED UPON STAGE (%)
    • TABLE 6: GLOBAL MELANOMA CANCER INCIDENCE AND MORTALITY, 2012 (NUMBER)
    • TABLE 7: GLOBAL OVARIAN CANCER INCIDENCE AND MORTALITY, 2012 (NUMBER)
    • TABLE 8: RELATIVE FIVE-YEAR SURVIVAL RATE FOR INVASIVE EPITHELIAL OVARIAN CANCER (%)
    • TABLE 9: GLOBAL CERVICAL CANCER INCIDENCE AND MORTALITY, 2012 (NUMBER)
    • TABLE 10: AVASTIN SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • TABLE 11: FIVE-YEAR RELATIVE SURVIVAL OF CERVIX UTERI CANCER PATIENTS, BASED ON STAGE AT DIAGNOSIS (%)
    • TABLE 12: GLOBAL LUNG CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)
    • TABLE 13: STAGES OF LUNG CANCER
    • TABLE 14: NON-SMALL CELL LUNG CANCER FIVE-YEAR SURVIVAL RATES BY STAGE (%)
    • TABLE 15: GLOBAL BRAIN CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)
    • TABLE 16: GLOBAL MULTIPLE MYELOMA CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)
    • TABLE 17: GLOBAL PANCREATIC CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)
    • TABLE 18: EXOCRINE PANCREATIC CANCER FIVE-YEAR SURVIVAL RATE (%)
    • TABLE 19: GLOBAL HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 20: U.S. HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 21: CANADIAN HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 22: EUROPEAN HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 23: JAPANESE HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 24: REST OF WORLD HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 25: KNOWN OCCUPATIONAL EXPOSURE RISKS ASSOCIATED WITH CANCER
    • TABLE 26: COLONY-STIMULATING FACTORS ON THE MARKET
    • TABLE 27: SELECTED INTERFERON PRODUCTS ON THE MARKET
    • TABLE 28: SELECTED DEVELOPMENTS IN INTERLEUKINS FOR CANCER THERAPY
    • TABLE 29: SELECTED APPROVED MONOCLONAL ANTIBODIES
    • TABLE 30: ELECTED MABS IN CLINICAL TESTING FOR INITIAL APPROVAL OR FOR ADDITIONAL INDICATIONS
    • TABLE 31: SELECTED CLINICAL TRIALS OF IMMUNOTHERAPY PRODUCTS
    • TABLE 32: GLOBAL MARKET FOR CANCER IMMUNOLOGY BY SEGMENT, THROUGH 2018 ($ MILLIONS)
    • TABLE 33: VALUE OF CANCER IMMUNOLOGY PRODUCTS IN THE U.S., THROUGH 2018 ($ MILLIONS)
    • TABLE 34: VALUE OF CANCER IMMUNOLOGY PRODUCTS IN CANADA THROUGH 2018 ($ MILLIONS)
    • TABLE 35: VALUE OF CANCER IMMUNOLOGY PRODUCTS IN THE EU THROUGH 2018 ($ MILLIONS)
    • TABLE 36: VALUE OF CANCER IMMUNOLOGY PRODUCTS IN JAPAN, THROUGH 2018 ($ MILLIONS)
    • TABLE 37: VALUE OF CANCER IMMUNOLOGY PRODUCTS FOR REST OF WORLD, (THROUGH 2018) ($ MILLIONS)
    • TABLE 38: CANCER IMMUNOLOGY MARKET BY INDICATION, THROUGH 2018 ($ MILLIONS)
    • TABLE 39: CANCER IMMUNOLOGY SALES BY INDICATION (PROSTATE CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 40: CANCER IMMUNOLOGY SALES BY INDICATION (BREAST CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 41: CANCER IMMUNOLOGY SALES BY INDICATION (LUNG CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 42: CANCER IMMUNOLOGY SALES BY INDICATION (BRAIN CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 43: CANCER IMMUNOLOGY SALES BY INDICATION (HEAD & NECK CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 44: CANCER IMMUNOLOGY SALES BY INDICATION (OVARIAN CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 45: CANCER IMMUNOLOGY SALES BY INDICATION (CERVICAL CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 46: CANCER IMMUNOLOGY SALES BY INDICATION (PANCREATIC CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 47: CANCER IMMUNOLOGY SALES BY INDICATION (MELANOMA CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 48: CANCER IMMUNOLOGY SALES BY INDICATION (OTHER CANCERS) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 49: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: COLONY STIMULATING FACTORS, THROUGH 2018 ($ MILLIONS)
    • TABLE 50: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: INTERFERON ALFA AND GAMMA PRODUCTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 51: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: INTERLEUKIN PRODUCTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 52: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: THERAPEUTIC MONOCLONAL ANTIBODIES, THROUGH 2018 ($ MILLIONS)
    • TABLE 53: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: CANCER VACCINES, THROUGH 2018 ($ MILLIONS)
    • TABLE 54: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: OTHER CANCER TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 55: GLOBAL ONCOLYTIC VIROTHERAPY MARKET, THROUGH 2023 ($ MILLIONS)
    • TABLE 56: ONCOLYTIC VIROTHERAPY MARKET BY REGION, THROUGH 2023 ($ MILLIONS)
    • TABLE 57: ONCOLYTIC VIROLOGY OUTLOOK BY CANCER TYPE, THROUGH 2023 ($ MILLIONS)
    • TABLE 58: SELECTED PATENTS IN CANCER IMMUNOLOGY AND VIROLOGY, 2005 TO 2013

LIST OF FIGURES

  • SUMMARY FIGURE: CANCER IMMUNOTHERAPIES MARKET BY GEOGRAPHICAL REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 1: GLOBAL HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • FIGURE 2: MARKET SHARES OF LEADERS IN CANCER IMMUNOLOGY, 2013 (%) 82
Back to Top